Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1) antibodies, have achieved breakthrough results in improving long-term survival rates in lung cancer. Although high levels of PD-L1 expression and tumor mutational burden have emerged as pivotal biomarkers, not all patients derive lasting benefits, and resistance to immune checkpoint blockade remains a prevalent issue. Comprehending the immunological intricacies of lung cancer is crucial for uncovering the mechanisms that govern responses and resistance to immunomodulatory treatments. This study aimed to explore the potential of peripheral immune markers in predicting treatment efficiency among lung cancer patients undergoing PD-1/PD-L1 checkpoint inhibitors.

Methods

SUBMITTER: Wang Y 

PROVIDER: S-EPMC11256628 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature